Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Definium TherapeuticsDFTX -1.58%28 EV-to-OCF is -37.04 as of Jul. 24, 2026. GuruFocus rates DFTX with a GF Score™ of 28/100. The stock has 5 warning signs investors should review. Among 1,410 Biotechnology companies, Definium Therapeutics ranks better than 89.43% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Definium Therapeutics's Enterprise Value is $5,362.70 Mil.
Definium Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was $-144.77 Mil. Therefore, Definium Therapeutics's EV-to-OCF for today is -37.04.
The historical rank and industry rank for Definium Therapeutics's EV-to-OCF or its related term are showing as below:
DFTX'
s EV-to-OCF Range Over the Past 10 Years
Min: -37.04 Med: 0 Max: -37.04
Current: -37.04
During the past 6 years, the highest EV-to-OCF of Definium Therapeutics was -37.04. The lowest was -37.04. And the median was .
DFTX's EV-to-OCF is ranked better than 89.43% of 1410
companies
in the Biotechnology industry
Industry Median: -3.315
vs DFTX: -37.04
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Definium Therapeutics's PE Ratio (TTM) for today is calculated as:
Definium Therapeutics's share price for today is $42.905.
Definium Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.490.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Definium Therapeutics's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Definium Therapeutics EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Definium Therapeutics's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Definium Therapeutics's EV-to-OCF falls into.
Definium Therapeutics's current Enterprise Value is $5,362.70 Mil.
Definium Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-144.77 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Definium Therapeutics (DFTX) has a EV-to-OCF of -37.04 as of Jul. 24, 2026. According to the industry distribution chart, Definium Therapeutics ranks #149 out of 1410 companies in the Biotechnology industry, placing it in the top 10.6%.
Is Definium Therapeutics' EV-to-OCF too high?
Definium Therapeutics' current EV-to-OCF is -37.04. Based on the distribution chart, Definium Therapeutics ranks #149 out of 1410 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Definium Therapeutics has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Definium Therapeutics' EV-to-OCF compare to LGND and XENE?
According to the Biotechnology industry distribution chart, Definium Therapeutics ranks #149 out of 1410 companies for EV-to-OCF. This places Definium Therapeutics in the top 11% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Definium Therapeutics's current EV-to-OCF is -37.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Definium Therapeutics stock overvalued right now?
Definium Therapeutics (DFTX) has a current EV-to-OCF of -37.04. The current EV-to-OCF is -37.04. Definium Therapeutics' overall GF Score™ is 28/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Definium Therapeutics (DFTX), the current EV-to-OCF is -37.04 as of Jul. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform.
28GF Score
Get the complete analysis for DFTX
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DFTX has been successfully added to your 
